Tau-Targeting Alzheimer's Drug Shows First Phase 2 Evidence of Slowing Cognitive Decline

Alzheimer's disease research has long focused on amyloid plaques, but tau protein tangles are equally implicated in brain degeneration. Diranersen, developed by Ionis and partnered with Biogen, takes a different approach — using antisense oligonucleotide technology to reduce tau production at the genetic level. The Phase 2 CELIA study represents a significant step forward in validating tau as a therapeutic target.

The trial enrolled 416 participants with mild cognitive impairment or mild Alzheimer's dementia, all amyloid-therapy naive, across multiple dose groups. Diranersen produced robust, sustained reductions in cerebrospinal fluid tau and tau pathology as measured by PET imaging — the clearest biological signal yet that the drug is hitting its target effectively in the human brain.

On cognitive outcomes, pre-specified analyses showed slowing of clinical decline across all studied doses. The effect was most pronounced at the lowest dose of 60 mg given every 24 weeks, an unusual finding that may suggest a therapeutic window or complex dose-response dynamics. The trial did not meet its primary endpoint — a dose-response measure on the Clinical Dementia Rating–Sum of Boxes at week 76 — a caveat that tempers enthusiasm.

Safety data were broadly consistent with earlier Phase 1b findings. Adverse event rates were comparable across most dose groups, though serious adverse events were more frequent at the highest dose, underscoring the importance of dose optimization in future trials.

Biogen has announced plans to advance diranersen into registrational development, with full data to be presented at the Alzheimer's Association International Conference 2026. For the longevity field, this trial offers cautious optimism: tau reduction may be a viable strategy to slow neurodegeneration, but larger confirmatory trials are needed before clinical translation becomes realistic.